Ocelot Bio is a clinical-stage biopharmaceutical company developing OCE-205, a therapeutic peptide targeting portal hypertension complications in end-stage liver disease, specifically hepatorenal syndrome with acute kidney injury and ascites. This treatment aims to improve patient outcomes by addressing life-threatening conditions associated with severe liver disease.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
End-stage liver disease (ESLD) can lead to portal hypertension, resulting in life-threatening complications such as hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites. Current treatments often fail to adequately address these complications, leading to poor patient outcomes.
Solution
Ocelot Bio is developing OCE-205, a therapeutic peptide designed to selectively address portal hypertension complications associated with ESLD. OCE-205's mechanism of action aims to improve outcomes for patients suffering from HRS-AKI and ascites. The drug is currently in Phase 2 clinical development.
Target Audience
The primary target audience includes patients with end-stage liver disease experiencing complications such as hepatorenal syndrome with acute kidney injury and ascites.
Features
- Therapeutic peptide targeting portal hypertension
- Designed to address complications of end-stage liver disease (ESLD)
- Specifically targets hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites
- Currently in Phase 2 clinical development